Bethesda, MD, United States of America

Leopold Kong

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 7.6

ph-index = 1


Location History:

  • La Jolla, CA (US) (2021)
  • Bethesda, MD (US) (2020 - 2023)

Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Innovative Breakthroughs by Leopold Kong in HIV-1 Vaccine Development**

Introduction

Leopold Kong, an accomplished inventor based in Bethesda, MD, has made significant contributions in the field of HIV research. With a portfolio containing four patents, he has focused his efforts on developing innovative vaccine immunogens to combat HIV infections.

Latest Patents

Kong's recent patents showcase his pioneering work in HIV-1 vaccine development. His inventions include HIV-1 GP140 immunogens that comprise modified NHR1 regions designed to stabilize pre-fusion envelope conformations. The first patent provides insights into HIV-1 vaccine immunogens, which include a soluble gp140-derived protein featuring a modified N-terminus of the HR1 region in gp41. Additionally, it describes HIV-1 Env-derived trimer proteins presented on a nanoparticle platform. The methods outlined in this patent aim to elicit immune responses or treat HIV infections effectively. The second patent complements the first by providing nucleic acids encoding similar HIV-1 GP140 immunogens, further exploring their potential in the fight against HIV.

Career Highlights

Throughout his career, Leopold Kong has worked with prominent research institutions, including The Scripps Research Institute and the National Center for AIDS/STD Control and Prevention at the Chinese Center for Disease Control and Prevention. His dedication to advancing HIV research has established him as a key player in the field.

Collaborations

Kong's collaborations with esteemed colleagues such as Ian A. Wilson and Linling He have propelled his research forward. Their collective expertise has contributed to groundbreaking developments in immunogen design and the quest for effective HIV vaccines.

Conclusion

Leopold Kong's innovative contributions and patents in HIV-1 vaccine immunogens not only represent his personal achievements but also reflect a broader commitment to improving global health. His ongoing work may pave the way for more effective treatments and vaccines, offering hope in the fight against HIV.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…